Save up -80% on Lifitegrast
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Xiidra
|$512.33||1 carton (60 ampules) 5%|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Xiidra coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Lifitegrast every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Lifitegrast volume of distribution
Following topical ocular administration to rats, dogs, or rabbits, lifitegrast was absorbed into the eye with a high level of exposure in anterior ocular tissues, the site of action, and limited distribution to the posterior segment. Systemic exposure following topical administration was found to be limited. Lifitegrast is highly bound to human serum albumin (mean of 94.8 to 97.6%). Binding to melanin was moderate in vitro (mean of 35.2-60.4% bound); however tissue distribution of [14C]-lifitegrast in pigmented and albino rats was comparable indicating that lifitegrast did not preferentially bind to melanin.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Lifitegrast
Lifitegrast is an FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It was approved in July, 2016 under the trade name Xiidra.
Lifitegrast mechanism of action
Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interactions support T-cell migration and activation, which promotes the release of cytokines that sustain inflammation. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 and may inhibit the secretion of key inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in dry eye disease is not known.
Dosage forms of Lifitegrast
|Xiidra Ophthalmic Solution||5%||12mL Eyedrops||$565.00|
|Xiidra||5%||1 carton (60 ampules)||$512.00|
Shire US Manufacturing Inc.
Indication of Lifitegrast
For the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Toxicity of Lifitegrast
Thirteen-week and 39-week repeat-dose ocular toxicity studies were conducted in New Zealand White rabbits and beagle dogs using the topical ocular route of administration with three times daily dosing (TID). Squinting or blinking immediately following dosing with lifitegrast was observed in both species, but was non-adverse. Other non-adverse findings in the 39-week studies included a slight increase in the severity of muscle fiber regeneration in the tongue of rabbits dosed ≥ 1.05 mg/eye/day, and minimal granulomatous inflammation of the tongue in a few dogs at the highest dose of 5.25 mg/eye/day. In both species, the no-observed-adverse-effect level (NOAEL) for ocular toxicity was 5.25 mg/eye/day (35 µL/eye of 5% formulation; TID), the highest dose tested. This NOAEL provides a 1.05-fold margin of safety in terms of total mg/day, and a 138-fold and 16-fold margin of safety when comparing systemic exposure (AUC) in rabbits and dogs, respectively, to the highest exposure reported in human clinical trials.
The NOAEL for the systemic toxicity of lifitegrast in beagle dogs following intravenous administration is 30 mg/kg/day, the highest dose tested in a 4-week study, providing a margin of safety of approximately 20,000-fold based on plasma AUC values. In rats, the NOAEL for systemic toxicity is 10 mg/kg/day, based on the following findings at 30 mg/kg/day in a 13-week intravenous study: an increase in incidence of thymic epithelial hyperplasia in females, renal/bladder/ureter and prostatic effects in one male, and testicular/epididymal effects in a second male. The NOAEL in rats provides a margin of safety of approximately 660-fold. Since human systemic exposure to lifitegrast following ocular administration at the RHOD is low, the applicability of animal findings to the risk of XIIDRA use is unclear.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Lifitegrast on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Lifitegrast now!
What is Xiidra?
Xiidra works by blocking a certain protein on the surface of the cells of your body. This protein can cause your eyes to not produce enough tears or produce tears that are not the right consistency for your eyes to be healthy. Xiidra eye drops are used to treat the symptoms of dry eye.
Follow all directions on label and package. Tell each of your health care providers about all your medical conditions, allergies, and all medications you use.